Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer

Daniel Reinhorn, Oded Jacobi, Oded Icht, Elizabeth Dudnik, Ofer Rotem, Alona Zer, Daniel A. Goldstein

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: The treatment paradigm of advanced non-small-cell lung cancer has recently changed with the introduction of immune checkpoint inhibitors (ICIs). It is common practice to continue treatment beyond progression (TBP) in selected cases. The aim of this study was to evaluate real life practice and outcomes related to TBP. Materials & methods: We retrospectively evaluated advanced non-small-cell lung cancer patients treated with ICI therapy and identified patients who were treated beyond progression. Results: Of 207 patients included in this analysis, 22% patients received TBP. A total of 36% achieved a clinical benefit. A total of 27% patients had a progression-free interval over 6 months after receiving TBP. Conclusion: A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control.

Original languageEnglish
Pages (from-to)235-243
Number of pages9
JournalImmunotherapy
Volume12
Issue number4
DOIs
StatePublished - Mar 2020

Keywords

  • immune checkpoint inhibitors
  • metastatic
  • nivolumab
  • non-small-cell lung cancer
  • pembrolizumab
  • treatment beyond progression

Fingerprint

Dive into the research topics of 'Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this